| abstract |
WHICH INCLUDES: a) AN INHIBITING DRUG OF LOW AQUEOUS SOLUBILITY IN A PROPHYLACTICALLY EFFECTIVE QUANTITY SUCH AS CYCLOOXYGENASA-2 SELECTIVE FROM FORMULA (I), WHERE R4 IS HO A GROUP C1-4, ALKYL, IS NOT ALCOXI, X IS NOT ALCOXI, X IS HALOGEN, Y and Z ARE INDEPENDENT CARBONS OR NITROGEN ATOMS DEFINING ADJACENT ATOMS OF A RING OF FIVE TO SIX MEMBERS WHICH IS NOT SUBSTITUTED OR SUBSTITUTED IN ONE OR MORE POSITIONS WITH GROUPS OF OXO, HALUS, ANTHYLOMETHYL, OR HALO, CONSISTYLOMETHYL, OR HALOGENO FURANONE, METHYLOPYRAZOLE ISOXAZOLA AND PYRIDINE, SELECTED SAID DRUG FROM CELECOXIB, DERACOXIB, VALDECOXIB AND JTE-522; b) A SOLVENT LIQUID, INCLUDING: i) AT LEAST ONE POLYETHYLENE GLYCOL OF 100 TO 10 000 MOLECULAR WEIGHT; ii) AT LEAST 0.01% TO 5% OF A RADICAL FREE OF SCANNING PHARMACEUTICALLY ACCEPTABLE ANTIOXIDANT SELECTED FROM VITAMIN E, MALIC ACID, SODIUM SULPHITE, GALATE PROPYL, AMONG OTHERS; iii) HYDROXYPROPYLMETILCELLULOSE AS A TURBIDITY REDUCER, OLEIC ACID AND A TERTIARY AMINE SUCH AS TRIETHANOLAMINE AND DIMETHYLAMINOETHANOL. WHERE, A SUBSTANTIAL PORTION OF (a) IS IN DISSOLVED OR SOLUBILIZED FORM IN (b), INCLUDING (a) AN AMINOSULFONYL FUNCTIONAL GROUP, CAPABLE OF REACTING WITH A POLYETHYLENE GLYCOL TO FORM AN ADDITIONAL COMPOUND |